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     Down syndrome (DS) is caused by three copies of human chromosome 
21 (HSA21) and results in abnormal craniofacial and appendicular bone phe-
notypes. The Ts65Dn mouse model of DS contains three copies of nearly half 
of the genes found on HSA21, and exhibits craniofacial skeletal phenotypes 
similar to those observed in humans with DS. We recently demonstrated ab-
normalities in the development and homeostasis of the appendicular skele-
ton of Ts65Dn mice. Femurs from trisomic mice exhibit alterations in trabec-
ular bone architecture and overall bone strength.  Furthermore, bone for-
mation rates were found to be significantly reduced, suggesting trisomy im-
pacts bone development and maintenance in Ts65Dn mice, and by extension 
humans with DS. DYRK1A is triplicated in both humans with DS and Ts65Dn 
mice and its protein acts as a kinase critical during development. Dyrk1A 
negatively regulates the nuclear localization and activation of Nfatc, a tran-
scription factor critical to signaling pathways associated with cell proliferation 
and bone development, and is overexpressed in the E9.5 Ts65Dn mandible 
precursor. We hypothesize that the previously documented Ts65Dn bone 
phenotype originates during embryonic development, and the presence of an 
extra copy of Dyrk1a contributes to the abnormal bone phenotype observed 
in Ts65Dn mice and humans with DS. To test our first hypothesis, analysis of 
the cartilage template and early bone precursor is being conducted on the 
femurs from embryonic day 17.5 trisomic and euploid embryos. To implicate 
the involvement of Dyrk1a in the DS bone phenotype, Ts65Dn mice are be-
ing treated with a known Dyrk1a inhibitor, EGCG, to determine if correcting 
the functional expression of Dyrk1a impacts the development of the Ts65Dn 
postnatal bone phenotype. Understanding the molecular mechanisms under-
lying DS bone phenotypes may help improve the quality of life for individuals 
with DS and provide viable options for the treatment of osteoporosis.   
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